Exosome-derived miRNAs and ovarian carcinoma progression

Carcinogenesis

Volumn 35, Issue 9, 2014, Pages 2113-2120

  Vaksman, Olga ^a   Tropé, Claes ^b,c   Davidson, Ben ^b,c   Reich, Reuven ^a,d  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ASCITIC FLUID; CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EXOSOMES; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MICE, SCID; MICRORNAS; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTOME; TUMOR BURDEN;

EID: 84906834990     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu130     Document Type: Article

References (30)

1. Weber,J.A. et al. (2010) The microRNA spectrum in 12 body fluids. Clin. Chem., 56, 1733-1741.
2. Wittmann,J. et al. (2010) Serum microRNAs as powerful cancer biomarkers. Biochim. Biophys. Acta, 1806, 200-207.
3. Mitchell,P.S. et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA, 105, 10513-10518.
4. Lawrie,C.H. et al. (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol., 141, 672-675.
5. Arroyo,J.D. et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA, 108, 5003-5008.
6. Smalheiser,N.R. (2007) Exosomal transfer of proteins and RNAs at synapses in the nervous system. Biol. Direct, 2, 35.
7. Valadi,H. et al. (2007) Exosome-mediated transfer of mRNAs and micro-RNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol., 9, 654-659.
8. Meckes,D.G. Jr et al. (2011) Microvesicles and viral infection. J. Virol., 85, 12844-12854.
9. Pant,S. et al. (2012) The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem. Pharmacol., 83, 1484-1494.
10. Siegel,R. et al. (2013) Cancer statistics, 2013. CA Cancer J. Clin., 63, 11-30.
11. Vaksman,O. et al. (2011) miRNA profiling along tumour progression in ovarian carcinoma. J. Cell. Mol. Med., 15, 1593-1602.
12. Iwanicki,M.P. et al. (2011) Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov., 1, 144-157.
13. Therasse,P. et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 92, 205-216.
14. Vergote,I. et al. (2000) Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J. Natl. Cancer Inst., 92, 1534-1535.
15. Chen,X. et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res., 18, 997-1006.
16. Kharaziha,P. et al. (2012) Tumor cell-derived exosomes: a message in a bottle. Biochim. Biophys. Acta, 1826, 103-111.
17. Taylor,D.D. et al. (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol., 110, 13-21.
18. Abusamra,A.J. et al. (2005) Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells. Mol. Dis., 35, 169-173.
19. Hood,J.L. et al. (2011) Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res., 71, 3792-3801.
20. Peinado,H. et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med., 18, 883-891.
21. Davidson,B., et al. (2014) The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol. Oncol, 133, 640-646.
22. Resnick,K.E. et al. (2009) The detection of differentially expressed micro-RNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol., 112, 55-59.
23. Kan,C.W. et al. (2012) Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer, 12, 627.
24. Lou,Y. et al (2010) MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int. J. Mol. Med., 26, 819-827.
25. Polytarchou,C. et al. (2011) Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res., 71, 4720-4731.
26. Eitan,R. et al. (2009) Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol. Oncol., 114, 253-259.
27. Park,Y.T. et al. (2013) MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J. Ovarian Res., 6, 18.
28. Davidson,B. et al. (2008) Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum. Pathol., 39, 87-95.
29. Creighton,C.J. et al. (2012) Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS ONE, 7, e34546.
30. Flavin,R. et al. (2009) miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int. J. Gynecol. Cancer, 19, 641-647.